Thus, we discovered a mechanism of prostate cancer lineage plasticity that provides an effective prediction strategy utilizing gene expression-based biomarkers for NEPC development through the association of activated ZBTB46 and accumulated NGF via stimulation of the CHRM4–AKT–MYCN pathway. This evidence concerns the gene ZBTB46 and prostate carcinoma.